Cugene Revenue and Competitors
Estimated Revenue & Valuation
- Cugene's estimated annual revenue is currently $3.1M per year.
- Cugene's estimated revenue per employee is $155,000
Employee Data
- Cugene has 20 Employees.
- Cugene grew their employee count by 33% last year.
Cugene's People
Name | Title | Email/Phone |
---|---|---|
1 | Director - Business Development, Licensing | Reveal Email/Phone |
2 | Associate Office Manager | Reveal Email/Phone |
3 | Sr. Clinical Trial Manager | Reveal Email/Phone |
4 | Senior Manager Business Operations | Reveal Email/Phone |
5 | Data Management Consultant | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
7 | In Vivo Scientist in Immuno-Oncology | Reveal Email/Phone |
8 | Research Associate | Reveal Email/Phone |
9 | Senior Scientist | Reveal Email/Phone |
10 | Associate Scientist | Reveal Email/Phone |
Cugene Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Cugene?
At Cugene, we develop medicines that harness the power of the human immune system to fight disease. Through highly innovative bioengineering, these novel therapeutics will provide specificity and efficacy while limiting unwanted side effects on neighboring healthy tissues. Focusing on areas with great unmet medical needs, Cugene’s team is dedicated to finding a Cure for Life.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.1M | 20 | -9% | N/A |
#2 | $3.1M | 20 | 0% | N/A |
#3 | $2.1M | 21 | -12% | $58M |
#4 | $2.1M | 21 | -5% | N/A |
#5 | $2.1M | 21 | 24% | N/A |